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ngio-Associated Migratory
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uscle Cell Migration in
evelopment of Restenosis
nd Atherosclerosis*
aul Holvoet, PHD,† Peter Sinnaeve, MD, PHD‡
euven, Belgium
igration of smooth muscle cells (SMCs) into the devel-
ping neointima is a pivotal step during atherosclerosis
evelopment in native vessels as well as in restenosis after
ascular intervention. Before migration can occur, a switch
f the SMC phenotype from the quiescent to the secretory
henotype and production of extracellular matrix are re-
uired (1–3).
See page 302
Previously, Blindt et al. (1) analyzed differences in gene
xpression pattern between the quiescent and the invasive
MC phenotype in vitro. They identified 9 clusters of
ifferentially regulated genes—the most important being
luster 3 containing 17 of the 47 deregulated genes, among
hem genes that are involved in cell communication, matrix
rganization, and cell adhesion and migration. One of them
as the angio-associated migratory cell protein (AAMP)
ene. It was first identified as a member of the immuno-
lobulin superfamily present in endothelial cells of all
uman tissues and shown to mediate cell–cell and cell–
ubstrate interactions (4).
In this issue of the Journal, Vogt et al. (5) demonstrated
n important functional role of AAMP for migration of
MC in vitro and for the development of neointimal
yperplasia in vivo. The AAMP overexpression resulted in
ncreased migration, whereas antibody- or silencing ribonu-
leic acid (RNA)–mediated inhibition of AAMP decreased
MC migration. Intraperitoneal administration of an anti-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Atherosclerosis and Metabolism Unit and ‡Division of Cardiology,(
epartment of Cardiovascular Diseases, Katholieke Universiteit Leuven, Leuven,
elgium.AMP antibody reduced neointimal SMC density and
eointima formation in apolipoprotein E–deficient mice.
heir data show for the first time that AAMP inhibition
ffers a unique way of downstream targeting cytosolic RhoA
athways resulting in inhibition of SMC migration.
Studies in experimental models demonstrated that me-
hanical stretch and interaction with extracellular matrix
eads to AAMP-mediated activation of RhoA. Activated
hoA then interacts with its effector rho-kinase (ROCK),
enerating the driving force for SMCs to migrate and to
ivide, leading to restenosis and atherosclerosis (Fig. 1).
irect inhibition of ROCK by fasudil and Y-27632 inhib-
ted vascular SMC migration (6). Similarly, 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitors or statins
locked RhoA pathways (7). However, it remains to be
etermined whether statins do this by impairing RhoA
ranslocation and consequent activation of RhoA or by
inding to ROCK (Fig. 1). In addition, activation of RhoA
athways induced endothelial cell migration (8) and endo-
helial progenitor cell differentiation (9,10). Furthermore,
hoA/ROCK activation in endothelial cells decreased en-
othelial nitric oxide (NO) synthase (eNOS) expression by
educing eNOS messenger RNA stability. Consequently,
OCK inhibitors or statins upregulated eNOS expression
11,12) (Fig. 1). In aggregate, animal studies suggested
hat RhoA pathways might contribute to several cardiovas-
ular pathologies, including arterial and pulmonary hyper-
ension (13–15), myocardial hypertrophy and remodeling
16), coronary artery spasm (17), atherosclerosis (18), and
estenosis (19,20).
Recent data obtained in patients, although sparse, support in
art ROCK’s involvement in these conditions. Fasudil atten-
ated coronary vasoconstrictor responses to acetylcholine in
atients with angina (21) and ameliorated myocardial ischemia
n patients having coronary microvascular spasm as well (22). It
lso prolonged symptom-limited exercise duration of patients
ith stable angina more than placebo without affecting heart
ate or blood pressure and was well-tolerated (23). Fasudil
mproved endothelium-dependent vasodilation and decreased
ascular resistance in patients with coronary heart disease as
ell (24,25). Indeed, oral fasudil during 1 month was shown in
n elegant study to significantly improve endothelium-
ependent brachial artery dilation in coronary artery disease
atients (n 13) but not in healthy subjects (n 16). Because
o effect of fasudil on endothelium-independent vasodilatation
as observed in either groups these findings suggest that
OCK inhibition at least in part restores decreased NO
vailability associated with atherosclerosis (25). To our knowl-
dge, proof of the effect of RhoA/ROCK inhibition on
ngioplasty- or stent-associated vascular SMC migration and
roliferation in patients in vivo is lacking to date. However,
nhibition of the RhoA/ROCK pathway does inhibit pulsatile
tretch-induced proliferation of human saphenous vein SMCs
26), indicating that clinical studies with inhibitors of this
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One important limitation of fasudil and Y-27632 is that
hey are not specific for ROCK. They inhibit several other
erine-threonine protein kinases, such as protein kinase A and
(27), which are also involved in several signaling pathways in
he cardiovascular system, particularly in the regulation of
yocardial contraction, hypertrophy, and remodeling (28).
herefore, the effects of currently available ROCK inhibitors
ight at least in part be due to blockage of other than RhoA
athways. However, there are no assays to evaluate how
ffective these agents are for inhibiting these specific pathways.
he structure of ROCK dimers has been determined, in search
f the mechanism for selectivity of ROCK. This structural
nalysis showed that subtle differences exist between the
OCK- and protein kinase A–bound conformations of the
nhibitors. These structural differences are expected to deter-
ine the relative selectivity of these compounds. In in vitro
inding studies, hydroxyfasudil—a metabolite of fasudil—was
ndeed selective for ROCK over protein kinase A (29). Its
Figure 1 Schematic Presentation of the Role of AAMP in Rho A
Angio-associated migratory cell protein (AAMP) causes the translocation and activa
RhoA interacts with its effector rho-kinase (ROCK), inducing migration of SMCs and
to inhibition of atherosclerosis and restenosis. Inhibition of AAMP in ECs and prog
ing to thrombosis. In contrast, AAMP inhibition might have an anti-thrombotic effec
production. Fasudil and Y-27432 are ROCK inhibitors (indicated by blunted arrows
effects of statins; they might also impair translocation of RhoA. GDP  guanosine
Flewell.igher selectivity remains, however, to be confirmed in vivo. (The current study shows that blocking AAMP offers a
ossibility to downstream inhibition of RhoA-dependent
athways and therefore the development of restenosis and
therosclerosis. In addition, it offers the advantage of a
ell-defined target allowing more specific inhibition with
igh-affinity antibodies, silencing RNA, or synthetic inhib-
tors (30). The AAMP blockage might also improve endo-
helial function and increase NO availability, therefore
nhancing its inhibitory effect on atherosclerosis and reste-
osis development. Some caution, however, is warranted.
ndeed, AAMP also regulates the motility of endothelial
ells (8) and is involved in endothelial progenitor cell
ifferentiation (9). Thus, blocking AAMP in endothelial
progenitor) cells might impair re-endothelialization, lead-
ng to delayed arterial healing and promoting thrombosis
31), and therefore prevent adequate prevention of resteno-
is. Finally, further studies on the role of AAMP in
egulating monocyte infiltration into the subendothelial
pace are needed. Indeed, ROCK inhibitors were shown to
nhibit atherosclerosis by preventing macrophage migration
tion That Contributes to Cardiovascular Pathologies
f RhoA in smooth muscle cells (SMCs) and endothelial cells (ECs). The activated
and attachment of endothelial progenitor cells. Inhibition of AAMP in SMCs leads
cells might impair re-endothelialization at the site of arterial injury, possibly lead-
stricting (impairing) endothelial nitric oxide (NO) synthase (eNOS) activity and NO
ition of ROCK is one of the putative (possible; not proven in humans) pleiotropic
hosphate; GTP  guanosine 5=-triphosphate. Figure illustration done by Robctiva
tion o
ECs
enitor
t by re
). Inhib
5=-dip32) and inflammation (33).
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Editorial Comment July 22, 2008:312–4In conclusion, this study is important because it draws our
ttention to the functional role of AAMP as a regulator of
MC migration. Further studies of the effect of AAMP
lockage on SMC migration and endothelial (progenitor)
ell and macrophage migration and inflammation, which are
mportant processes in the development of atherosclerosis
nd restenosis, are warranted.
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